Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.

AFEYAN NOUBAR

Klinger Shannon Thyme

Hoge Stephen

Hussain Abbas

The FDA's VRBPAC panel will meet on June 18 to review Moderna's mRNA-based flu vaccine (mFlusiva/mRNA-1010) for adults 50 and older. The vaccine met all efficacy criteria in trials, but the panel will scrutinize the choice of standard-dose flu vaccine as a comparator and efficacy data limitations in older adults. Moderna seeks full approval for ages 50-64 and accelerated approval for 65+, with an FDA decision deadline of August 5.

FDA Panel Set To Debate Moderna Flu Shot

The Nasdaq fell 1.15% on tech and chip weakness, with major semiconductor stocks like Nvidia, Broadcom, and Micron Technology declining due to profit-taking. The S&P 500 dropped 0.57%, while the Dow Jones rose 0.64% as investors rotated toward industrial, transportation, and financial sectors. CoreWeave surged nearly 10% on bullish analyst sentiment, while Robinhood Markets slid following layoff announcements. The Federal Reserve began its first meeting under new Chair Kevin Warsh.

Stock Market Today, June 16: Nvidia, Broadcom, and Micron Technology Lead Drop in Nasdaq

U.S. stocks showed mixed performance on Tuesday as investors rotated out of technology into financials, utilities, and industrials. The Dow Jones reached record highs at 52,185.49, while the Nasdaq 100 declined 1.4%. Oil prices fell to $77/barrel on expectations of a Strait of Hormuz reopening deal. Federal Reserve Chair Kevin Warsh prepares for his first policy meeting with markets pricing in a 97% probability of unchanged rates.

Dow Jones Hit Record Highs As Oil Drops To $77: Stock Market Today

Moderna announced organizational changes with President Stephen Hoge taking expanded oversight of R&D, manufacturing, and commercial operations. The company reported Q1 adjusted loss of $1.18 per share (better than expected) and revenue of $389 million (exceeding estimates). Moderna reiterated 2026 revenue growth guidance of up to 10% and expects potential launches of three new products in 2027-2028, including flu-COVID combination and norovirus vaccines. The company also anticipates key clinical milestones for its oncology and rare disease candidates.

Moderna Strengthens Commercial Strategy As Pipeline Advances

Parabilis Medicines raised $670 million in the largest biotech IPO on record, soaring 58% on its first trading day. The company's innovative Helicon platform targets previously 'undruggable' proteins for cancer treatment. While the technology shows promise with lead candidate zolucatetide entering phase 3 trials, the company faces significant losses ($145 million last year) and remains years away from generating revenue, making it suitable only for aggressive investors willing to wait several years.

Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?

Trader & Student of the Market  • Co-Founder of @TraderLion+@Deepvue • The Trader's Handbook https://t.co/wwGdE6Xg79 • Sharing lessons from 100+ Market Wizards

Richard Moglen

Founder SELLTHESPIKE CAFL Stockmarket Trading Investing  TrainTheEye Options Stocks Cars 97%biz/3% jokes Know your limit$ JDMBABroker Learn 2 think for yourself

Maliboooooom !

Former scientist at a major biotech for 15+ yrs, now I trade stocks daily. Tweets are for entertainment only - not investment advice.

Swing & day trader
Tweets are my opinion only and not a recommendation to buy or sell any security.
I don't Have any subservice/ WhatsApp group /Telegram group!

Moderna Inc (MRNA) Stock Price, Analysis & Trade Signals